Frankfurt - Delayed Quote EUR
REGENXBIO Inc. (RB0.F)
6.30
-0.05
(-0.79%)
At close: May 9 at 8:00:14 AM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 11 | 9 |
| Avg. Estimate | 105.35M | 35.7M | 325.28M | 279.43M |
| Low Estimate | 20M | 16.5M | 80M | 80.34M |
| High Estimate | 132.4M | 122.89M | 453.16M | 457M |
| Year Ago Sales | 15.62M | 22.3M | 83.33M | 325.28M |
| Sales Growth (year/est) | 574.37% | 60.14% | 290.36% | -14.10% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| RB0.F | -- | -- | -- | -- |
| S&P 500 | 13.06% | 3.09% | 8.02% | 13.74% |
Upgrades & Downgrades
| Maintains | Goldman Sachs: Neutral to Neutral | 4/17/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/21/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/20/2025 |
| Maintains | Chardan Capital: Buy to Buy | 3/20/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/17/2025 |
| Maintains | Chardan Capital: Buy to Buy | 3/14/2025 |